Revelations from a German study regarding the alleged lack of efficacy and the potential for harm in people taking one antidepressant could reveal a critical flaw in the way these drugs are tested in animals. The antidepressant reboxetine (Edronax, Norebox, Prolift, Solvex, Davedax or Vestra) made by Pfizer is currently not approved by the US Food & Drug Administration for the US market but is prescribed elsewhere in the world. Now, a meta-analysis of studies suggests that efficacy is close to zero and that it may have very undesirable side-effects. According to Scientific American's correspondent, "the study [found] that reboxetine produced more side effects (noted as "adverse events") than placebo (as might be expected), but with no positive effects at all." Many antidepressants are not very effective, showing success in less than two-thirds of patients, but reboxetine is far less effective than that, the study suggests. In animals no serious adverse reactions were reported.